P109 Efficacy and safety of a 3-monthly depot formulation of degarelix compared with goserelin in prostate cancer

Authors :: Laurence Klotz
Bertrand Tombal
B.E. Persson
T. Tammela
E.D. Crawford
M.C. Gittelman
J.M. Wolff
Neal D. Shore
Tine Kold Olesen
Heather Payne
Source :: European Urology Supplements. 11:228
Publication Year :: 2012
Publisher :: Elsevier BV, 2012.

Subjects :: Oncology
medicine.medical_specialty
business.industry
Depot
Urology
Goserelin
medicine.disease
Prostate cancer
chemistry.chemical_compound
chemistry
Internal medicine
medicine
Degarelix
business
medicine.drug

Full Text Access

Tools